PharmaCyte Biotech Sets 1-for-19 Reverse Split, PMCB Trades Adjusted Nov 13

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) will convert every nineteen existing shares into one under a 1-for-19 reverse stock split approved by its board, the company announced on November 11, 2026. The split legally takes effect at 4:01 p.m. Eastern Time on November 12, 2026, and PMCB is expected to open on the Nasdaq Capital Market on November 13, 2026 under a new CUSIP, 71715X 302, still trading as "PMCB." Outstanding shares fall from roughly 10,755,649 to approximately 566,087.

Context — Why Did PharmaCyte Biotech Reverse Split Its Stock?

The stated purpose is listing compliance. PharmaCyte said the split is intended to lift the per-share trading price of its common stock enough to regain compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market.

The company did not disclose the specific bid price threshold in the announcement, nor the current trading price of PMCB, nor how long a compliance period it has been granted. Readers looking for the exact deficiency notice terms will not find them in the release.

The authorization path matters here. Stockholders approved the reverse split at the company's annual meeting held on March 30, 2026, roughly seven and a half months before the board set the ratio and the effective date. That gap tells you the board retained discretion over timing and magnitude rather than committing to a fixed exchange ratio in March.

The ratio itself is the comparable the company gives. A 1-for-19 conversion is aggressive relative to the more common 1-for-2 through 1-for-10 structures that microcaps use to satisfy exchange listing standards. Because the ratio is fixed at nineteen, the arithmetic effect on the share count is deterministic: the same equity is repackaged into a far smaller number of units.

The split arrives in a US equity market where index-level direction has been driven by large-cap technology and rate expectations rather than microcap biotech. PharmaCyte is a single Nasdaq Capital Market issuer; its corporate action carries no read-through to sector indices.

Data — What the Numbers Show

The share count is the cleanest measure of magnitude. Outstanding common stock falls from approximately 10,755,649 shares as of November 11, 2026, to approximately 566,087 shares after the conversion. That is a reduction of roughly 95% in unit count.

The ratio and the share count reconcile: dividing 10,755,649 by nineteen yields approximately 566,087, which matches the post-split figure the company published.

Item	Pre-Split	Post-Split
Shares outstanding	~10,755,649	~566,087
Conversion ratio	19 shares	1 share
Authorized shares	Unchanged	Unchanged
Ticker	PMCB	PMCB
CUSIP	Prior	71715X 302

Two structural details sit outside the headline ratio. First, the total authorized number of shares will not be reduced, so the company retains the same share-issuance capacity even though outstanding units shrink by a factor of nineteen. Second, proportional adjustments apply to the exercise and conversion prices of outstanding stock options, warrants and convertible securities, and to the number of shares issued and issuable under the company's stock incentive plans.

The report gives no peer comparison. No sector-relative multiple, no comparable issuer action, and no market capitalization figure are disclosed, so none can be cited here.

Analysis — What the Reverse Split Means for PMCB Holders

A reverse split changes the unit count, not the economic ownership percentage. A holder of nineteen pre-split shares owns one post-split share, and that share represents the same fractional claim on the company as the nineteen did. The company's total authorized share capacity staying flat is the detail with second-order consequences: the board keeps the ability to issue the same number of authorized shares into a much smaller outstanding base, which is the mechanism by which dilution ratios shift after a reverse split.

Fractional shares are handled in cash, not in stock. The company said no fractional shares will be issued, and holders otherwise entitled to a fraction receive cash equal to that fraction multiplied by the closing sales price on the Nasdaq Capital Market on November 12, 2026 — the last trading day before split-adjusted trading begins — as adjusted for the split. That means the cash-out price is set by a pre-split close, then adjusted, not by the post-split opening print.

The limitation worth stating plainly: a reverse split addresses the nominal share price, not the underlying business. Regaining a minimum bid price does not alter revenue, cash position, pipeline or clinical timelines, and the report discloses none of those. Investors treating the split as a fundamental catalyst are reading a mechanical corporate action as an operating one.

Positioning follows the mechanics. Holders in book-entry form or through a broker need take no action; positions adjust automatically subject to each broker's own processing timelines. Certificate holders must route physical shares through the transfer agent, Equiniti Trust Company, LLC, which will send exchange instructions. That administrative step is where retail holders typically experience the most friction, and it is the reason pre-split certificate holders sometimes find themselves temporarily unable to trade.

Outlook — What to Watch After November 13

The first checkpoint is the November 13, 2026 open, when PMCB begins trading on a split-adjusted basis under the new CUSIP 71715X 302. The opening print against the adjusted November 12 close is the first observable measure of whether the price level satisfies the exchange's minimum bid requirement.

Second, watch for any Nasdaq notification confirming regained compliance. The company did not state in the announcement whether compliance is automatic upon the adjusted trading price, or whether a formal review period applies. That confirmation is the event that resolves the stated purpose of the split.

Third, the fractional-share cash payments will settle through Equiniti on a schedule the company did not disclose. Holders with residual fractions should track that distribution separately from their equity position.

The report names no price levels, no support or resistance zones and no moving averages, so there are no technical thresholds to cite. The only level that matters in the company's own framing is the Nasdaq minimum bid price, which it did not quantify.

Frequently Asked Questions

What does a 1-for-19 reverse split mean for my PharmaCyte shares?

Every nineteen shares you hold convert automatically into one share. Your percentage ownership of the company does not change, and the total value of your position at the moment of conversion is the same, ignoring price movement. If your holding is not evenly divisible by nineteen, the remainder is paid to you in cash rather than issued as a fractional share. Book-entry and brokerage holders take no action.

Will PharmaCyte's stock price go up because of the reverse split?

The per-share price mechanically rises by roughly the split ratio, but the company's market value is unchanged by the conversion itself. The split is intended to satisfy a Nasdaq minimum bid price listing requirement, which is a compliance objective rather than a valuation one. Post-split price direction depends on buying and selling after November 13, not on the conversion arithmetic.

Do I need to do anything to receive my post-split PharmaCyte shares?

Most holders do not. Shares held electronically in book-entry form adjust automatically, and holders through a bank, broker or other nominee have positions adjusted subject to that firm's own processes. Only holders of physical stock certificates must act: Equiniti Trust Company, LLC, the transfer agent, will send instructions for exchanging certificates for book-entry shares or new certificates.

Bottom Line

PharmaCyte's 1-for-19 reverse split cuts outstanding shares to about 566,087 on November 13 to chase Nasdaq minimum bid compliance, changing the unit count but not the business.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.